Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | PREP | P48147 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5508174 | 0.90 | CA12 (0.33) | CA12CA1CA9PREPALOX15 | |
| SCHEMBL5508843 | 0.80 | ALOX15 (0.50) | ALOX15ALOX12 | |
| SCHEMBL5497729 | 0.72 | HTR2C (0.48) | ALOX15ALOX12 | |
| SCHEMBL10042955 | 0.71 | CYP19A1 (0.58) | CA12CA1CA9PREPALOX15 | |
| SCHEMBL5499423 | 0.70 | ESR2 (0.57) | ALOX15ALOX12 | |
| SCHEMBL25723894 | 0.68 | MAPT (0.41) | CA12CA1CA9PREPALOX15 | |
| SCHEMBL22863907 | 0.68 | MAPT (0.41) | CA12CA1CA9PREPALOX15 | |
| SCHEMBL22816944 | 0.68 | ESR2 (0.47) | CA12CA1CA9PREP | |
| SCHEMBL1516112 | 0.68 | ESR2 (0.47) | CA12CA1CA9PREP | |
| SCHEMBL4827559 | 0.68 | CA12 (0.40) | CA12CA1CA9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778656-A1 | BENZOXAZEPINE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006023242-A1 | BENZOXAZEPINE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-02 | — | — | WO | disclosed |
| US-20060040917-A1 | Benzoxazepine derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040917-A1 | Benzoxazepine derivatives as selective estrogen receptor modulators | GPER1, ESR2, ESR1 | CA12 2771/4885CA1 3305/4885CA9 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.